DYNE THERAPEUTICS INC (DYN) Stock Price & Overview
NASDAQ:DYN • US26818M1080
Current stock price
The current stock price of DYN is 18.35 USD. Today DYN is down by -2.6%. In the past month the price increased by 23.49%. In the past year, price increased by 160.65%.
DYN Key Statistics
- Market Cap
- 3.028B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.54
- Dividend Yield
- N/A
DYN Stock Performance
DYN Stock Chart
DYN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DYN. When comparing the yearly performance of all stocks, DYN is one of the better performing stocks in the market, outperforming 94.97% of all stocks.
DYN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DYN. DYN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DYN Earnings
DYN Forecast & Estimates
20 analysts have analysed DYN and the average price target is 40.73 USD. This implies a price increase of 121.97% is expected in the next year compared to the current price of 18.35.
DYN Groups
Sector & Classification
DYN Financial Highlights
Over the last trailing twelve months DYN reported a non-GAAP Earnings per Share(EPS) of -3.54. The EPS decreased by -5.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.59% | ||
| ROE | -45.9% | ||
| Debt/Equity | 0.15 |
DYN Ownership
DYN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 369.265B | ||
| AMGN | AMGEN INC | 15.01 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DYN
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Company Info
IPO: 2020-09-17
DYNE THERAPEUTICS INC
1560 Trapelo Road
Waltham MASSACHUSETTS 02451 US
CEO: Joshua Brumm
Employees: 258
Phone: 18009279800
DYNE THERAPEUTICS INC / DYN FAQ
Can you describe the business of DYNE THERAPEUTICS INC?
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Can you provide the latest stock price for DYNE THERAPEUTICS INC?
The current stock price of DYN is 18.35 USD. The price decreased by -2.6% in the last trading session.
Does DYNE THERAPEUTICS INC pay dividends?
DYN does not pay a dividend.
What is the ChartMill rating of DYNE THERAPEUTICS INC stock?
DYN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is DYNE THERAPEUTICS INC (DYN) stock traded?
DYN stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for DYNE THERAPEUTICS INC?
DYNE THERAPEUTICS INC (DYN) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of DYN stock?
DYNE THERAPEUTICS INC (DYN) has a market capitalization of 3.03B USD. This makes DYN a Mid Cap stock.